Oral Health, Saliva Bacteria, and Disease Activity in Children With JIA: A Cross-Sectional Study. (JIA)
Association of Oral Health Status and Salivary Microbiota With Disease Activity in Children With Juvenile Idiopathic Arthritis: A Cross-Sectional Study.
The goal of this observational study is to learn about the relationship between disease activity and oral health status in children with juvenile idiopathic arthritis (JIA). The main question it aims to answer is:
Is disease activity associated with oral health in children with JIA? Do children with active disease have poorer oral health compared to those in clinical remission? Participants already receiving routine rheumatology care for JIA will undergo a single study visit. At that visit, disease activity will be assessed, an oral health examination will be performed, and saliva samples will be collected. Based on the disease activity assessment, participants will be classified into two groups: those with active disease and those in remission. Oral health measures and saliva-related parameters will be compared between the two groups.
This study is expected to provide preliminary evidence to help identify JIA children at higher risk of oral health problems and to support the integration of oral health evaluation into comprehensive JIA management.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children, characterised by alternating periods of active disease and remission. Despite therapeutic advances, joint involvement in the hands, wrists, or temporomandibular joints can hinder daily oral hygiene practices, and long-term medication use may affect the oral microenvironment, increasing the risk of dental caries and gingivitis. In current routine rheumatology follow-up in China, oral health status is not systematically assessed; it is usually addressed only when the child complains of symptoms, leading to delayed recognition and intervention.
This single-centre, cross-sectional observational study aims to compare oral health status between JIA children with different levels of disease activity and to preliminarily explore the association of salivary local biological characteristics with disease activity. No intervention is applied. All data are collected at a single time point during a regular outpatient visit.
Study Population Children aged 6 to 16 years who meet the ILAR classification criteria for JIA are eligible. Exclusion criteria include use of systemic antibiotics within the past 3 months, ongoing fixed orthodontic treatment, presence of other systemic conditions known to affect oral health (e.g., diabetes, Sjögren's syndrome), or inability to cooperate with the examination.
Grouping and Assessments At enrolment, two experienced rheumatologists independently classify each participant as having "active disease" or "clinical remission" based on standardised clinical assessment (joint examination, physician global assessment, and routine laboratory inflammatory markers). During the same visit, the following are completed: (1) collection of demographic and disease-related data; (2) a comprehensive oral clinical examination conducted by trained dentists, covering dental hard tissues, periodontal soft tissues, and oral hygiene status; and (3) collection of unstimulated whole saliva for subsequent analysis of local inflammatory markers and microbial community profiles. All data are recorded using coded identifiers to protect participant privacy.
Statistical Analysis Oral health parameters will be compared between the two groups, with multivariable methods used to control for potential confounders such as age, sex, and disease duration. The correlation between continuous disease activity scores and composite oral health indices will be evaluated. Saliva data will be explored for associations with disease activity and oral health parameters.
Clinical Significance This study addresses a long-neglected but clinically relevant question: whether disease activity in JIA is associated with oral health status. If children with active disease show poorer oral conditions, this would support the need for rheumatologists to actively inquire about oral hygiene habits and dental history during follow-up, and to consider incorporating basic oral health screening (e.g., questions on brushing, gum bleeding, toothache) into routine visits. Through this work, we aim to promote clinical awareness of oral health issues in children with chronic diseases and advocate for the inclusion of oral health assessment as a fundamental component of JIA chronic disease management, fostering collaboration between paediatric rheumatology and dentistry, and ultimately improving patients' quality of life.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Biyu Shen, PhD
- Numéro de téléphone: 86＋13862937317
- E-mail: shenbiyu@126.com
Sauvegarde des contacts de l'étude
- Nom: Yuan Yuan Xiang, Graduate Student
- Numéro de téléphone: 86＋15995792738
- E-mail: 2115746605@qq.com
Lieux d'étude
-
-
Pudongxinqu
-
Shanghai, Pudongxinqu, Chine, 200135
- Recrutement
- Shanghai Children's Medical Center, Lujiazui Campus, affiliated to Shanghai Jiao Tong University School of Medicine
-
Contact:
- Biyu Biyu Shen, PhD
- Numéro de téléphone: 86＋13862937317
- E-mail: shenbiyu@126.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Children aged 6 to 16 years.
- Diagnosed with juvenile idiopathic arthritis according to the International League of Associations for Rheumatology (ILAR) classification criteria, excluding the systemic-onset subtype.
For the active disease subgroup, all of the following must be met:
- Presence of active arthritis as determined by the attending rheumatologist;
- Planned initiation or adjustment of disease-modifying antirheumatic drugs (DMARDs) or biologic agents within 1 month after enrolment;
- Meeting the following disease activity criterion: JADAS-27 score > 1. For the remission subgroup, the following must be met: JADAS-27 score ≤ 1 and clinically stable disease.
- Able to cooperate with oral examination and saliva sample collection.
- Written informed consent provided by a legal guardian, with assent obtained from the child.
Exclusion Criteria:
- Use of systemic antibiotics within 3 months prior to enrolment, or use of mouthwash containing antibiotics, corticosteroids, or chlorhexidine within 1 month prior to enrolment.
- Diagnosis of other autoimmune diseases (e.g., systemic lupus erythematosus, Sjögren's syndrome), chronic inflammatory diseases (e.g., inflammatory bowel disease), diabetes mellitus, congenital heart disease, or other systemic conditions that may affect the study outcomes.
- Presence of acute infection at the time of sampling or examination (e.g., body temperature > 37.5°C, upper respiratory tract infection, acute oral infection).
- Significant cognitive or behavioural impairment that prevents cooperation with study procedures.
- Ongoing or planned orthodontic treatment within the next 6 months.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
|---|
|
JIA group
Children aged 6 to 16 years diagnosed with juvenile idiopathic arthritis according to the ILAR classification criteria, receiving routine rheumatology care at the study site.
Participants are classified into active disease or clinical remission subgroups based on standardised clinical assessment at enrolment.
No intervention is applied.
|
|
Healthy Control Group
Healthy children aged 6 to 16 years with no history of chronic inflammatory or autoimmune diseases, recruited from the same city or community as the JIA group.
No intervention is applied.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Oral Health Status
Délai: At baseline, during a single routine outpatient visit immediately after written informed consent is obtained.
|
A comprehensive oral health examination is conducted by trained dentists in accordance with the World Health Organization Oral Health Surveys: Basic Methods.
The examination covers dental hard tissue status, periodontal soft tissue status, oral hygiene status, oral mucosal assessment, and oral health-related behaviours.
For dental caries assessment, each tooth is visually and tactilely examined under standardised lighting, and indices are calculated for permanent and primary dentition as appropriate.
Periodontal status is evaluated using standardised probes to assess gingival bleeding and pocket depth.
Oral hygiene is assessed following WHO recommendations; prior to evaluation, a disclosing agent is applied to tooth surfaces to visualise plaque, enabling standardised scoring of debris and calculus on representative surfaces.
The oral mucosa is inspected for any soft tissue abnormalities.
Oral health behaviours, including toothbrushing habits, dietary practices, and dental attendance.
|
At baseline, during a single routine outpatient visit immediately after written informed consent is obtained.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Salivary Microbiota
Délai: Baseline visit (fasting morning)
|
The samples are analysed for microbial composition using 16S rRNA gene sequencing, assessing microbial diversity, relative abundance of major taxa, and compositional differences between study groups.
In addition, levels of soluble inflammatory proteins are measured to evaluate local inflammatory status.
|
Baseline visit (fasting morning)
|
|
Disease Activity Assessment
Délai: Baseline visit
|
Disease activity is assessed by experienced rheumatologists using standardised clinical evaluation at the baseline visit.
The assessment includes joint examination (swollen and tender joint count), physician global assessment of disease activity on a visual analogue scale, and routine laboratory inflammatory markers (erythrocyte sedimentation rate and C-reactive protein level).
Based on the combined findings, participants are classified as having active disease or being in clinical remission.
|
Baseline visit
|
Collaborateurs et enquêteurs
Publications et liens utiles
Publications générales
- [1]Klingberg G.,Hallberg U.Oral health-Not a priority issue A Grounded Theory analysis of barriers for young patients with disabilities to receive oral health care on the same premise as others.Eur.J.Oral Sci.2012;120:232-238. [2]Szabo Y Z,Slavish D C,Graham-Engeland J E.The effect of acute stress on salivary markers of inflamma-tion:a systematic review and meta-analysis[J].Brain Behav Immun,2020,88:887-900. [3]Walton AG,Welbury RR,Thomason JM,Foster HE.Oral health and juvenile idiopathic arthritis:a review.Rheumatology(Oxford).2000 May;39(5):550-5. [4]LANGE L，THIELE G M，MCCRACKEN C，et al.Symptoms of periodontitis and antibody responses to Porphyromonas gingivalis in juvenile idiopathic arthritis.Pediatr Rheumatol Online J，2016，14(1):8. [5]Romero-Sanchez C,Malagon C,Vargas C,et al.Porphyromonas gingivalis and IgG1 and IgG2 subclass antibodies in patients with juvenile idiopathic arthritis[J].J Dent Child(Chic),2017,84(2):72-79. [6]Titusson C,Jansson L,Modin C,Lundmark A,Eriksson K,Adler L,Yucel-Lindberg T.Salivary Inflammatory Mediator Profiles in Periodontal and Peri-Implant Health and Disease:A Cross-Sectional Study.Clin Implant Dent Relat Res.2025 Feb;27(1):e70002. [7]Halbig JM,Jönsson B,Gil EG,Åstrøm AN,Rypdal V,Frid P,Augdal TA,Fischer J,Cetrelli L,Rygg M,Lundestad A,Tylleskär K,Nordal E;Norwegian JIA Study-Temporo-mandibular Involvement,Oral Health,Uveitis,Bone Health,Quality of Life in Children with Juvenile Idiopathic Arthritis.Oral health-related quality of life,impaired physical health and orofacial pain in children and adolescents with juvenile idiopathic arthritis-a prospective multicenter cohort study.BMC Oral Health.2023 Nov 20;23(1):895. [8]Savioli C,Silva CA,Ching LH,Campos LM,Prado EF,Siqueira JT.Dental and facial characteristics of patients with juvenile idiopathic arthritis.Rev Hosp Clin Fac Med Sao Paulo.2004 Jun;59(3):93-8.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- SCMCIRB-K2026053-1
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .